機能的なP2Y2ヌクレオチド受容体は,コラー付きウサギの頸動脈における尿素5'-トリフォスファート誘発の親密性多発症を媒介する
Cheikh I Seye1, Qiongman Kong, Laurie Erb
1Department of Biochemistry, University of Missouri-Columbia, Columbia, Mo 65212, USA. seyec@missouri.edu
Circulation
|November 20, 2002
まとめ
細胞外尿素5'-三リン酸 (UTP) とアデノシン5'-三リン酸 (ATP) はP2Y2受容体を活性化させ,滑らかな筋肉細胞の増殖と内臓の増殖を促進します. この研究は,P2Y2受容体を実証しています.
科学分野:
- 血管生物学 血管生物学
- 細胞シグナル伝達 細胞信号伝達
- 分子医学は分子医学である.
背景:
- 細胞外ウリジン5'-トリフォスファート (UTP) は,P2Y2核酸受容体を通して,滑らかな筋肉細胞 (SMC) を活性化させます.
- P2Y2受容体mRNAは内臓病変で上昇しますが,内臓増殖におけるその役割は不明です.
研究 の 目的:
- P2Y2受容体の血管損傷と内臓増殖における役割を調査する.
- P2Y2受容体の活性化がSMCの増殖とネオインティマの形成に寄与するかどうかを判断する.
主な方法:
- シリコンカラーモデルを使用して,ウサギの頸動脈の血管損傷を誘導しました.
- Fura-2イメージングは,P2Y受容体アゴニストに対する反応として,SMCにおけるカルシウム濃度の変化を評価した.
- オステオポントン発現はUTPとATPへの反応として測定され,発現を抑制するためにP2Y2アンチセンセオリゴヌクレオチドが使用されました.
主要な成果:
- ネオインティマ形成前のSMCにおけるP2Y2受容体mRNAを高調化するカラーの配置.
- UTPとATPは,UDPではないが,細胞内カルシウムが増加し,機能的なP2Y2受容体のアップレギュレーションを確認した.
- 周血管のUTP注入は,ネオインティマルの発達とマクロファージの浸透を大幅に改善しました.
- UTPとATPは,SMCにおけるオステオポントンの発現を刺激し,P2Y2反感覚オリゴヌクレオチドによって抑制された効果である.
結論:
- P2Y2受容体は,親密性多発症の発生に重要な役割を果たしています.
- 発見は,P2Y2受容体の活性化が動脈硬化症と回復症に寄与することを示唆しています.
- P2Y2受容体へのターゲティングは,血管増殖性疾患の治療戦略を提供することができる.
関連する概念動画
GPCRs Regulate Adenylyl Cylase Activity
6.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Receptors: β Subtype
3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81


